FDA Accepts Supplemental Application for AVAPRO by Sanofi
The FDA has accepted a supplemental application for AVAPRO (irbesartan) from Sanofi.
Company
Pharmaceutical intelligence for Sanofi with 18 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.